{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T22:39:29Z","timestamp":1794955169358,"version":"4.9.1"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,2,16]],"date-time":"2022-02-16T00:00:00Z","timestamp":1644969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,2,16]],"date-time":"2022-02-16T00:00:00Z","timestamp":1644969600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Neurotrophic keratopathy (NK) is a rare, degenerative ocular disease characterized by reduction or loss of corneal sensitivity and development of non-healing corneal epithelial defects and ulcers. Cenegermin, a recombinant human nerve growth factor (rhNGF) eye drop solution, is the first drug approved for the treatment of\u00a0NK. The aim of our study is to evaluate the long-term efficacy of this innovative topical treatment in patients with NK.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Retrospective, consecutive, observational case series study from a single-center setting (Department of Sense Organs, University Sapienza of Rome, Rome, Italy). 18 patients with diagnosis of stage 2 or 3 NK, treated with Cenegermin 20 mcg\/ml eye drops were followed for up to 48\u00a0months. Recurrence of lesion during follow-up was evaluated at 12, 24, 36, and 48\u00a0months. In addition, corneal sensitivity, Schirmer tear test, and visual acuity (VA) were recorded at baseline, end of treatment, and at 12, 24, 36, and 48\u00a0months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Three patients experienced recurrence of persistent epithelial defects (PEDs) within 12\u00a0months and one patient experienced recurrence of a corneal ulcer within 36\u00a0months. Corneal sensitivity was significantly improved at all timepoints (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.05). Significant improvements in visual acuity and tear production were seen at the completion of treatment as well as at 12, 24, and 36\u00a0months (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.05) when compared to baseline.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>A single 8-week treatment regimen of Cenegermin eye drops has clinical efficacy that can persist for up to 48\u00a0months. The long-term clinical utility of treatment with Cenegermin for NK was demonstrated through the low rate of lesion recurrence along with improvements in corneal sensitivity and tear production.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13023-022-02236-6","type":"journal-article","created":{"date-parts":[[2022,2,16]],"date-time":"2022-02-16T04:04:01Z","timestamp":1644984241000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Long-term clinical efficacy of topical treatment with recombinant human nerve growth factor in neurotrophic keratopathy: a novel cure for a rare degenerative corneal disease?"],"prefix":"10.1186","volume":"17","author":[{"given":"Alice","family":"Bruscolini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Marenco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe Maria","family":"Albanese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8974-991X","authenticated-orcid":false,"given":"Alessandro","family":"Lambiase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Sacchetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,2,16]]},"reference":[{"key":"2236_CR1","first-page":"571","volume":"8","author":"M Sacchetti","year":"2014","unstructured":"Sacchetti M, Lambiase A. Diagnosis and management of neurotrophic keratitis. Clinical ophthalmology (Auckland, NZ). 2014;8:571\u20139.","journal-title":"Clinical ophthalmology (Auckland, NZ)"},{"issue":"5","key":"2236_CR2","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/S0014-4835(03)00050-2","volume":"76","author":"LJ Muller","year":"2003","unstructured":"Muller LJ, Marfurt CF, Kruse F, Tervo TM. Corneal nerves: structure, contents and function. Exp Eye Res. 2003;76(5):521\u201342.","journal-title":"Exp Eye Res"},{"key":"2236_CR3","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.preteyeres.2018.04.003","volume":"66","author":"HS Dua","year":"2018","unstructured":"Dua HS, Said DG, Messmer EM, Rolando M, Benitez-Del-Castillo JM, Hossain PN, et al. Neurotrophic keratopathy. Prog Retin Eye Res. 2018;66:107\u201331.","journal-title":"Prog Retin Eye Res"},{"issue":"4","key":"2236_CR4","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1002\/jcp.25623","volume":"232","author":"L Mastropasqua","year":"2017","unstructured":"Mastropasqua L, Massaro-Giordano G, Nubile M, Sacchetti M. Understanding the pathogenesis of neurotrophic keratitis: the role of corneal nerves. J Cell Physiol. 2017;232(4):717\u201324.","journal-title":"J Cell Physiol"},{"issue":"4","key":"2236_CR5","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1097\/ICU.0b013e3283543b61","volume":"23","author":"A Lambiase","year":"2012","unstructured":"Lambiase A, Sacchetti M, Bonini S. Nerve growth factor therapy for corneal disease. Curr Opin Ophthalmol. 2012;23(4):296\u2013302.","journal-title":"Curr Opin Ophthalmol"},{"issue":"17","key":"2236_CR6","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1056\/NEJM199804233381702","volume":"338","author":"A Lambiase","year":"1998","unstructured":"Lambiase A, Rama P, Bonini S, Caprioglio G, Aloe L. Topical treatment with nerve growth factor for corneal neurotrophic ulcers. N Engl J Med. 1998;338(17):1174\u201380.","journal-title":"N Engl J Med"},{"key":"2236_CR7","doi-asserted-by":"crossref","unstructured":"Bonini S, Lambiase A, Rama P, Caprioglio G, Aloe L. Topical treatment with nerve growth factor for neurotrophic keratitis. Ophthalmology. 2000;107(7):1347\u201351; discussion 51\u20132.","DOI":"10.1016\/S0161-6420(00)00163-9"},{"issue":"2","key":"2236_CR8","first-page":"283","volume":"149","author":"A Lambiase","year":"2011","unstructured":"Lambiase A, Mantelli F, Sacchetti M, Rossi S, Aloe L, Bonini S. Clinical applications of NGF in ocular diseases. Arch Ital Biol. 2011;149(2):283\u201392.","journal-title":"Arch Ital Biol"},{"issue":"3","key":"2236_CR9","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/s40259-013-0079-5","volume":"28","author":"MP Ferrari","year":"2014","unstructured":"Ferrari MP, Mantelli F, Sacchetti M, Antonangeli MI, Cattani F, D\u2019Anniballe G, et al. Safety and pharmacokinetics of escalating doses of human recombinant nerve growth factor eye drops in a double-masked, randomized clinical trial. BioDrugs\u202f: clinical immunotherapeutics, biopharmaceuticals and gene therapy. 2014;28(3):275\u201383.","journal-title":"BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy"},{"issue":"9","key":"2236_CR10","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1016\/j.ophtha.2018.03.004","volume":"125","author":"S Bonini","year":"2018","unstructured":"Bonini S, Lambiase A, Rama P, Filatori I, Allegretti M, Chao W, et al. Phase I trial of recombinant human nerve growth factor for neurotrophic keratitis. Ophthalmology. 2018;125(9):1468\u201371.","journal-title":"Ophthalmology"},{"issue":"9","key":"2236_CR11","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1016\/j.ophtha.2018.02.022","volume":"125","author":"S Bonini","year":"2018","unstructured":"Bonini S, Lambiase A, Rama P, Sinigaglia F, Allegretti M, Chao W, et al. Phase II randomized, double-masked, vehicle-controlled trial of recombinant human nerve growth factor for neurotrophic keratitis. Ophthalmology. 2018;125(9):1332\u201343.","journal-title":"Ophthalmology"},{"issue":"1","key":"2236_CR12","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.ophtha.2019.08.020","volume":"127","author":"SC Pflugfelder","year":"2020","unstructured":"Pflugfelder SC, Massaro-Giordano M, Perez VL, Hamrah P, Deng SX, Espandar L, et al. Topical recombinant human nerve growth factor (cenegermin) for neurotrophic keratopathy: a multicenter randomized vehicle-controlled pivotal trial. Ophthalmology. 2020;127(1):14\u201326.","journal-title":"Ophthalmology"},{"key":"2236_CR13","doi-asserted-by":"crossref","unstructured":"Mastropasqua L, Manuela L, Dua HS, D'Uffizi A, Di Nicola M, Calienno R, et al. In vivo evaluation of corneal nerves and epithelial healing after treatment with recombinant nerve growth factor for neurotrophic keratopathy. American journal of ophthalmology. 2020.","DOI":"10.1016\/j.ajo.2020.04.036"},{"key":"2236_CR14","doi-asserted-by":"crossref","unstructured":"Di Zazzo A, Varacalli G, Mori T, Coassin M. Long-term restoration of corneal sensitivity in neurotrophic keratopathy after rhNGF treatment. Eur J Ophthalmol. 2020:1120672120953343.","DOI":"10.1177\/1120672120953343"},{"key":"2236_CR15","doi-asserted-by":"crossref","unstructured":"Mantelli F, Nardella C, Tiberi E, Sacchetti M, Bruscolini A, Lambiase A. Congenital corneal anesthesia and neurotrophic keratitis: diagnosis and management. Biomed Res Int. 2015;2015:805876.","DOI":"10.1155\/2015\/805876"},{"key":"2236_CR16","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1016\/S0161-6420(99)90444-X","volume":"106","author":"FE Kruse","year":"1999","unstructured":"Kruse FE, Rohrschneider K, Volcker HE. Multilayer amniotic membrane transplantation for reconstruction of deep corneal ulcers. Ophthalmolog. 1999;106:1504\u201310.","journal-title":"Ophthalmolog"},{"key":"2236_CR17","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-021-05431-6","author":"M Sacchetti","year":"2021","unstructured":"Sacchetti M, Komaiha C, Bruscolini A, Albanese GM, Marenco M, Colabelli Gisoldi RAM, et al. Long-term clinical outcome and satisfaction survey in patients with neurotrophic keratopathy after treatment with cenegermin eye drops or amniotic membrane transplantation. Graefes Arch Clin Exp Ophthalmol. 2021. https:\/\/doi.org\/10.1007\/s00417-021-05431-6.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"1","key":"2236_CR18","first-page":"127","volume":"104","author":"M Sacchetti","year":"2020","unstructured":"Sacchetti M, Lambiase A, Schmidl D, Schmetterer L, Ferrari M, Mantelli F, et al. Effect of recombinant human nerve growth factor eye drops in patients with dry eye: a phase IIa, open label, multiple-dose study. Br J Ophthalmol. 2020;104(1):127\u201335.","journal-title":"Br J Ophthalmol"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-022-02236-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-022-02236-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-022-02236-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,16]],"date-time":"2022-02-16T04:06:09Z","timestamp":1644984369000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-022-02236-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,16]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["2236"],"URL":"https:\/\/doi.org\/10.1186\/s13023-022-02236-6","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,16]]},"assertion":[{"value":"17 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Investigational Review Board (IRB) of University Sapienza of Rome, Italy (IRB number 5338) with informed consent obtained at follow-up visits.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Images are entirely unidentifiable and there are no details on individuals reported within the manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"AL, MS, and AB are paid consultants for Domp\u00e9 Farmaceutici SpA, Milan, Italy. GMA and MM have no conflicts of interest to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"57"}}